Lipella Pharmaceuticals (LIPO) News Today $2.44 +0.03 (+1.24%) (As of 02:37 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Maxim Group Keeps Their Buy Rating on Lipella Pharmaceuticals, Inc. (LIPO)November 21 at 5:44 AM | markets.businessinsider.comLipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose GroupNovember 21 at 5:30 AM | globenewswire.comLipella Pharmaceuticals Faces Nasdaq Delisting Risk Amid Compliance ChallengesNovember 16, 2024 | markets.businessinsider.comLipella issued patent by USPTO for liposomal drug delivery platformNovember 13, 2024 | markets.businessinsider.comLipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery PlatformNovember 12, 2024 | globenewswire.comLipella Pharmaceuticals Announces 1-for-8 Reverse Stock SplitNovember 1, 2024 | globenewswire.comLipella Pharmaceuticals to Present at 2024 Spartan Capital Investor ConferenceOctober 29, 2024 | globenewswire.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery PlatformOctober 15, 2024 | finanznachrichten.deLipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery PlatformOctober 15, 2024 | globenewswire.comLipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual SummitOctober 9, 2024 | globenewswire.comLipella Pharmaceuticals (NASDAQ:LIPO) Stock, Short Interest ReportSeptember 26, 2024 | benzinga.comBuy Rating on Lipella Pharmaceuticals Backed by Promising Phase 2a Results for Oral Lichen Planus TreatmentSeptember 25, 2024 | markets.businessinsider.comPRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness MonthSeptember 25, 2024 | globenewswire.comLipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus ResearchAugust 22, 2024 | globenewswire.comLipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ ConferenceAugust 21, 2024 | globenewswire.comLipella Pharmaceuticals Second Quarter 2024 Earnings: US$0.12 loss per share (vs US$0.27 loss in 2Q 2023)August 18, 2024 | finance.yahoo.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical TrialAugust 14, 2024 | finanznachrichten.deBuy Rating Affirmed: Lipella Pharmaceuticals’ Innovative Drug Delivery and Clinical Advancements Propel OptimismAugust 13, 2024 | markets.businessinsider.comLipella doses first two subjects in Phase IIa oral lichen planus treatment trialAugust 12, 2024 | finance.yahoo.comLipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical TrialAugust 12, 2024 | globenewswire.comLipella Pharmaceuticals (NASDAQ:LIPO) Stock Quotes, Forecast and News SummaryJuly 31, 2024 | benzinga.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First PatientsJuly 29, 2024 | finanznachrichten.deLipella stock soars 200% on Phase 2 study initiationJuly 29, 2024 | msn.comWhy Is Lipella Pharmaceuticals (LIPO) Stock Up 149% Today?July 29, 2024 | investorplace.comLipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First PatientsJuly 29, 2024 | globenewswire.comLipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen PlanusMay 31, 2024 | globenewswire.comLIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q1 2024May 29, 2024 | investorplace.comLipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 29, 2024 | globenewswire.comFollowing Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2bMay 21, 2024 | globenewswire.comLipella Pharmaceuticals First Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.19 loss in 1Q 2023)May 13, 2024 | finance.yahoo.comLipella Pharmaceuticals Expands its Advisory Board to Include Oncology ExpertiseApril 17, 2024 | finance.yahoo.comLipella Pharmaceuticals Expands its Advisory Board to Include Oncology ExpertiseApril 17, 2024 | globenewswire.comLipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024April 5, 2024 | globenewswire.comLipella Pharmaceuticals Announces Type C Meeting For LP-10 - Quick FactsApril 3, 2024 | markets.businessinsider.comLipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic CystitisApril 3, 2024 | globenewswire.comLipella Pharmaceuticals Inc. (NASDAQ:LIPO) Insider Jonathan H. Kaufman Purchases 30,000 SharesMarch 20, 2024 | insidertrades.comPRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare DiseaseMarch 7, 2024 | finance.yahoo.comLipella Pharma's IND Application For LP-410 Gets FDA's ApprovalMarch 5, 2024 | markets.businessinsider.comLipella Pharmaceuticals Inc Ordinary Shares LIPOMarch 3, 2024 | morningstar.comLipella Pharmaceuticals Full Year 2023 Earnings: US$0.77 loss per share (vs US$0.64 loss in FY 2022)March 1, 2024 | finance.yahoo.comLipella Pharmaceuticals to Present at PropThink Digital Investor ConferenceFebruary 20, 2024 | finance.yahoo.comLipella Pharmaceuticals to Present at PropThink Digital Investor ConferenceFebruary 20, 2024 | globenewswire.comLipella Pharmaceuticals Inc. (LIPO)February 9, 2024 | finance.yahoo.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones AccomplishedDecember 20, 2023 | finanznachrichten.deLipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones AccomplishedDecember 20, 2023 | finance.yahoo.comLipella Pharmaceuticals Inc Ordinary SharesDecember 9, 2023 | morningstar.comLipella Pharma: FDA Grants Orphan Designation For LP-310 To Treat Oral Graft-versus-Host DiseaseNovember 10, 2023 | markets.businessinsider.comFDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host DiseaseNovember 10, 2023 | finance.yahoo.comLipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq RulesOctober 25, 2023 | finance.yahoo.comLipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq RulesOctober 24, 2023 | finance.yahoo.com Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin LIPO Media Mentions By Week LIPO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LIPO News Sentiment▼-0.550.47▲Average Medical News Sentiment LIPO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LIPO Articles This Week▼30▲LIPO Articles Average Week Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TLPH News Today EGRX News Today TSBX News Today INDP News Today PHXM News Today CDT News Today IPA News Today KPRX News Today IMNN News Today MBIO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LIPO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
